Veracyte increased its full-year revenue guidance after beating second-quarter top- and bottom-line expectations, citing continued demand for its Decipher and Afirma cancer tests. The company raised its 2026 revenue outlook and testing revenue range, supported by Decipher prostate test growth and Afirma thyroid test momentum. Veracyte also highlighted new product activity, including launching Prosigna in the US and securing Medicare coverage for its whole-genome sequencing-based TrueMRD Monitoring Test in muscle-invasive bladder cancer. The guidance increase signals investor confidence tied to payer acceptance and test utilization rather than broad platform risk.